Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
0.4783
-0.0346 (-6.75%)
Mar 31, 2025, 2:25 PM EDT - Market open

Company Description

Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.

Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma.

The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial.

In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector.

The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Century Therapeutics, Inc.
Century Therapeutics logo
Country United States
Founded 2019
IPO Date Jun 18, 2021
Industry Biotechnology
Sector Healthcare
Employees 150
CEO Brent Pfeiffenberger

Contact Details

Address:
25 North 38th Street, 11th Floor
Philadelphia, Pennsylvania 19104
United States
Phone 267 817 5790
Website centurytx.com

Stock Details

Ticker Symbol IPSC
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001850119
CUSIP Number 15673T100
ISIN Number US15673T1007
Employer ID 84-2040295
SIC Code 2836

Key Executives

Name Position
Brent Pfeiffenberger M.B.A., Pharm.D. Chief Executive Officer and Director
Dr. Adrienne Farid Ph.D. Chief Development Officer, CCO and Head of Early Development
Dr. Gregory Russotti Ph.D. Chief Technology and Manufacturing Officer
Dr. Morgan Conn Ph.D. Chief Financial Officer
Dr. Chad A. Cowan Ph.D. Chief Scientific Officer
Dr. Shane Williams Ph.D. Chief People Officer
Michael Naso Ph.D. Senior Vice President of Cell Engineering
Dr. Nick Trede M.D., Ph.D. Senior Vice President and Head of Clinical Development
Katja Buhrer SVice President, Head of Corporate Affairs and Strategy
Douglas Carr CPA Senior Vice President of Finance and Operations and Secretary

Latest SEC Filings

Date Type Title
Mar 20, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 19, 2025 8-K Current Report
Mar 19, 2025 10-K Annual Report
Mar 10, 2025 144 Filing
Mar 10, 2025 144 Filing
Mar 10, 2025 144 Filing
Feb 28, 2025 8-K Current Report
Feb 18, 2025 144 Filing
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 3, 2025 144 Filing